Joseph M. Limber
Chairman of the Board
Joseph M. Limber was elected Molecular Insight’s Non-Executive Chairman of the Board effective August 10, 2009. A Board member since September 2008, Mr. Limber has 35 years of experience in all aspects of the management and financing of pharmaceutical and biotechnology companies. Currently, Mr. Limber is the President and Chief Executive Officer of Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostics company focusing on the identification, stratification, and treatment of gastrointestinal, oncology and autoimmune diseases and disorders. Prior to joining Prometheus in 2003, Mr. Limber was interim Chief Executive Officer for Deltagen, Inc., a provider of drug discovery tools and services to the life sciences industry. He has also served as President and Chief Executive Officer of ACLARA Biosciences, Inc. (now Monogram Biosciences, Inc.), President and Chief Operating Officer of Praecis Pharmaceuticals (acquired by GlaxoSmithKline, plc), and as Executive Vice President of SEQUUS Pharmaceuticals, Inc. (acquired by ALZA Corporation and now a part of the Johnson & Johnson family of companies), respectively. In addition, he held senior management positions with the International Division of Syntex Corporation (now Hoffman-La Roche, Ltd.) as well as in marketing and sales with Ciba-Geigy Corporation (now Novartis AG). Mr. Limber serves on the Board of Directors of Prometheus Laboratories, Inc. and Panacos Pharmaceuticals, Inc. and holds a B.A. from Duquesne University.
John W. Babich, Ph.D.
Executive Vice President, Chief Scientific Officer, President of Research and Development
John W. Babich, Ph.D., a founder of the company in 1997, serves as Executive Vice President, Chief Scientific Officer, President of Research and Development and as a member of the Board of Directors. Most recently he served as the Company’s President, Chief Executive Officer and Chief Scientific Officer. He has been an active researcher in the field of molecular imaging and targeted radionuclide therapy for the past 25 years. Prior to joining the Company, he was Assistant Professor of Radiology at Harvard Medical School and Staff Radiopharmaceutical Chemist at Massachusetts General Hospital (MGH), Boston, Massachusetts. Prior to joining MGH, Dr. Babich was Principal Scientist and Head of the Radiopharmaceutical Section at the Institute of Cancer Research in England. Dr. Babich's current research efforts focus on molecular imaging in cardiovascular disease, oncology and neurology. His previous research experience includes detection of breast and colorectal cancer using monoclonal antibodies, pharmacological and in vivo biological studies of novel small molecules for targeted therapy of neuroblastoma, the use of peptide-based molecular imaging agents for the detection of infection and cancer, and the use of positron emission tomography for the study of drug interactions in humans. He has published more than 100 research articles in a variety of peer-reviewed journals as well as several book chapters and invited reviews. He is inventor or co-inventor of numerous issued and pending patents licensed to or property of the Company. He is also co-inventor of a cardiac imaging product currently marketed by Mallinckrodt-TycoHealthcare, Inc. as Ultra-Tag. Dr. Babich recently served as President of the Society of Nuclear Medicine's Radiopharmaceutical Science Council. Dr. Babich received a B.S. in pharmaceutical sciences from St. John’s University, an M.S. from University of Southern California, and a Ph.D. from the University of London.
Daniel Frank
Director
Daniel Frank has served as a member of the Board of Directors since 2004. Since 2001, he has worked at Cerberus Capital Management, L.P., a private investment firm. From 1999 to 2001, Mr. Frank served as a Managing Director and Portfolio Manager of ACI Capital Strategic Fund, a New York-based hedge fund, and prior to that he served as a portfolio manager for Chatterjee/Soros Fund Management. From 1979 to 1996, Mr. Frank was employed by Fidelity Management and Research (Fidelity Investments). While at Fidelity, Mr. Frank served as Assistant Portfolio Manager to Peter Lynch on the Magellan Fund and as Vice President and sole Portfolio Manager, for over a decade, of the Fidelity Strategic Opportunities/Special Situations Fund. In 1996, Mr. Frank was ranked by Barron’s magazine as one of the Top 100 U.S. Mutual Fund Managers. Mr. Frank served on the Board of Directors of i-STAT Corporation from 2001 until its sale to Abbott Laboratories in 2003. From 1986 until its sale in 1996, Mr. Frank was board member and largest stockholder of Corsearch, a New York-based trademark research firm that is now part of CCH-Wolters Klower Inc. Mr. Frank received a B.S. in business administration from Boston University School of Management.
Scott Gottlieb, M.D.
Director
Scott Gottlieb, M.D., has served as a member of the Board of Directors since 2007. Dr. Gottlieb, a practicing physician, joined the American Enterprise Institute earlier this year after several years at the U.S. Food and Drug Administration (FDA). Dr. Gottlieb was the Deputy Commissioner for Medical and Scientific Affairs at the FDA from 2005 to 2007. Prior to his appointment as Deputy Commissioner, he served at the FDA in a number of senior capacities, including Senior Advisor for Medical Technology for the FDA Commissioner and Director of Medical Policy Development. During his time in government, he also served as Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services (CMS), and is a frequent contributor to leading journals and publications. Dr. Gottlieb is a Partner at Arcoda Capital and a Venture Partner at New Enterprise Associates. Dr. Gottlieb received his B.A. in economics from Wesleyan University in Middletown, Connecticut and an M.D. degree from the Mount Sinai School of Medicine in New York.
Daniel L. Peters
President and Chief Executive Officer
Daniel L. Peters was appointed President and Chief Executive Officer of Molecular Insight Pharmaceuticals and elected to the Board of Directors in May 2009. Mr. Peters is developing business strategies, assessing market opportunities and driving value creation as Molecular Insight moves into its next stage of product development, strategic partnering and product commercialization. Prior to joining the Company, he served as President and Chief Executive Officer of GE Healthcare, where he had responsibility for all aspects of the business, including global P&L, long-term growth strategies, marketing, sales, business development, R&D and manufacturing. Mr. Peters was instrumental in expanding the business portfolio. Under his leadership, the radiopharmaceutical business of Amersham Health was successfully integrated into GE Healthcare, taking the more descriptive name of Medical Diagnostics. Mr. Peters had been Chief Operating Officer of Amersham Health, where he had worldwide operational responsibilities. While at Amersham, Mr. Peters recruited new talent to strengthen the R&D organization and reorganized the business structure to refocus on emerging markets. Earlier in his career, Mr. Peters was President of Nycomed Amersham, Inc., a North and South America diagnostic and therapeutic pharmaceutical subsidiary of Amersham Plc. Mr. Peters also served as President of Nycomed, Inc. and held executive positions, including the role of President of the U.S. pharmaceuticals business for Sanofi Winthrop. Mr. Peters is currently Chairman of the Board of Phadia AB, and also serves on the board of MDRNA, Inc. He holds a B.S. degree from Western Illinois University.
David M. Stack
Director
David M. Stack has served as a member of the Board of Directors since 2006 and has more than 25 years of experience in the pharmaceutical and biotechnology industries. Mr. Stack has been Executive Partner of MPM Capital since 2005 and a Managing Partner of Stack Pharmaceutical, Inc. since 2004. From 2001 until 2004 he was President, Chief Executive Officer of The Medicines Company. Previously, Mr. Stack was President, General Manager at Innovex, Inc., where he held positions of increasing responsibility from 1995. He was Vice-President, Business Development/Marketing at Immunomedics from 1993 until 1995 and prior to that he was with Roche Laboratories in positions of increasing responsibility from 1981 until 1993, most recently as Director, Business Development and Planning, Infectious Disease, Oncology, and Virology. He currently serves as a Director of Bio-Imaging Technologies, Inc., Medsite, Inc., PepTx, Inc. and ORx Pharma, Pty. Ltd. Mr. Stack holds a B.S. degree in Biology from Siena College and a B.S. degree in Pharmacy from the Albany College of Pharmacy.
Lionel Sterling
Director
Lionel Sterling joined the Board of Directors in 2007, when Molecular Insight became a publicly traded company. In 1987, Mr. Sterling founded Equity Resources Inc., a private investment firm, where he has served as President since 1987. He is currently a member of the Board of Directors of Third Wave Technologies. From 1988 to 1993, Mr. Sterling served as co-Founder and Managing Partner of Whitehead/Sterling, a private investment firm, and from 1981 to 1985, he served as Chairman of the Board of Rayovac Corporation. In addition, from 1981 to 1982, Mr. Sterling served as Executive Vice President and member of the Board of Directors of United Brands Company, and from 1974 to 1981 he was with American Can Company, where he served as a Chief Financial Officer and Sector Executive. He has also served as Vice President and a Managing Director of Donaldson, Lufkin & Jenrette, Inc.'s venture capital and private investment activities, as well as having held various operating and financial responsibilities at ITT Corporation within its technology and services divisions. Mr. Sterling has held a number of public and private Board positions, served as an advisor to venture capital and buyout firms, and invested in a number of privately held companies. Mr. Sterling has been on the Board of Overseers of New York University Schools of Business and on the Board of Overseers of the Dartmouth Institute, and serves with a number of non-profit organizations. Mr. Sterling received a B.A. from Brooklyn College in New York and an M.B.A. in Finance from New York University.
Harry Stylli, Ph.D.
Director
Harry Stylli, Ph.D., has served as a member of our Board of Directors since 2004. Dr. Stylli is the former Chief Executive Officer and President of Sequenom. From 2004 until 2005 he was President and Chief Executive Officer of Xenecor. Dr. Stylli co-founded Aurora Biosciences in 1995, where he served as Senior Vice President of Screening Technology and New Ventures from 2001 to 2002 and as Senior Vice President of Commercial Development from 1999 to 2001. In 2001, following the merger between Aurora and Vertex Pharmaceuticals, Dr. Stylli served as President of Aurora Biosciences and Panvera. From 2002 to 2003, he served as President and Chief Executive Officer of CovX Pharmaceuticals. From 1987 to 1995, Dr. Stylli held varying positions of increasing responsibility in the global discovery organization of GlaxoSmithKline. He currently serves as a Director of Scitegic, a privately-held bioinformatics company. Dr. Stylli received a B.S. from the University of East London, an M.B.A from Open University in the United Kingdom and his Ph.D. from London University.